Latest & greatest articles for quetiapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quetiapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quetiapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quetiapine

1. Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial

Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial Antipsychotic agents, such as quetiapine fumarate, are frequently overprescribed for indications not supported by clinical evidence, potentially causing harm.To investigate if peer comparison letters targeting high-volume primary care prescribers of quetiapine meaningfully reduce their prescribing.Randomized clinical trial (intent to treat) conducted (...) from 2015 to 2017 of prescribers and their patients nationwide in the Medicare program. The trial targeted the 5055 highest-volume primary care prescribers of quetiapine in 2013 and 2014 (approximately 5% of all primary care prescribers of quetiapine).Prescribers were randomized (1:1 ratio) to receive a placebo letter or 3 peer comparison letters stating that their quetiapine prescribing was high relative to their peers and was under review by Medicare.The primary outcome was the total quetiapine

2018 EvidenceUpdates

2. Quetiapine

Quetiapine Top results for quetiapine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for quetiapine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Quetiapine

Quetiapine USE OF QUETIAPINE IN PREGNANCY 0344 892 0909 USE OF QUETIAPINE IN PREGNANCY (Date of issue: March 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Quetiapine is an atypical antipsychotic used in the treatment (...) of schizophrenia, bipolar disorder, other psychoses and major depressive disorder. The considerable data regarding first trimester exposure to quetiapine does not suggest an overall increased risk of congenital malformation. More limited data does not support an association between quetiapine exposure and small for gestational age or preterm delivery. A single study has suggested an increased risk of spontaneous abortion, while no studies have investigated the risk of intrauterine death following in utero

2014 UK Teratology Information Service

4. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of pharmacological treatments in all phases of bipolar disorder, comparing quetiapine with olanzapine and olanzapine plus lithium as well as with other

2013 NHS Economic Evaluation Database.

5. Generalised anxiety disorder: quetiapine

Generalised anxiety disorder: quetiapine Gener Generalised anxiety disorder: quetiapine alised anxiety disorder: quetiapine Evidence summary Published: 15 May 2013 nice.org.uk/guidance/esuom12 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary There is some evidence (...) that quetiapine monotherapy improves the symptoms of generalised anxiety disorder (GAD) compared with placebo, and limited evidence suggests that it is not more effective than antidepressants. Other limited evidence suggests that adding quetiapine to an antidepressant does not improve symptoms in GAD that has not responded to the antidepressant alone. People taking quetiapine are more likely to discontinue treatment because of adverse effects compared with placebo or active treatment. Licencing status

2013 National Institute for Health and Clinical Excellence - Advice

6. Is use of quetiapine for sleep evidence-based?

Is use of quetiapine for sleep evidence-based? September - December 2010 79 © Tel.: 604 822•0700 Fax: 604 822•0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Is use of quetiapine for sleep evidence-based? The healthy subject study evaluated 14 males using a randomized, double-blind, crossover, placebo-controlled (...) , single-center design. Placebo or quetiapine at 25 and 100 mg doses were given on 3 consecutive nights with a 4-day washout period before crossover. Polysomnographic recordings were made nightly and subjective sleep-rating questionnaires completed each morn- ing. Both doses of quetiapine produced statisti- cally significant improvements in objective and subjective ratings of sleep, including total sleep time, sleep efficiency, sleep latency and duration of stage 2 sleep. The 100 mg dose increased peri

2011 Therapeutics Letter

7. Seroquel (quetiapine fumarate)

Seroquel (quetiapine fumarate) Drug Approval Package: Seroquel (quetiapine fumarate) NDA #020639/S-049/S-054 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Seroquel (quetiapine fumarate) Tablets Company: AstraZeneca Pharmaceuticals LP Application No.: 020639/S-049/S-054 Approval Date: 07/08/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2011 FDA - Drug Approval Package

8. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials

Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Cheung G, Stapelberg J CRD summary The authors concluded (...) that, using the Neuropsychiatric Inventory and the Clinical Global Impression of Change scale,quetiapine was statistically more effective than placebo for the behavioural and psychological symptoms of dementia in elderly people; the clinical significance of the effects was questionable. Limitations to the review methods mean that the reliability of the authors' conclusion is unclear. Authors' objectives To evaluate the efficacy of quetiapine for the behavioural and psychological symptoms of dementia

2011 DARE.

9. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline

Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline | Evidence-Based (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Article Text Therapeutics Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics

2011 Evidence-Based Mental Health

10. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study (PubMed)

Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol.Prospective, randomized, double-blind, placebo-controlled study.Three academic medical centers.Thirty-six adult intensive care unit patients with delirium (Intensive Care Delirium (...) Screening Checklist score > or = 4), tolerating enteral nutrition, and without a complicating neurologic condition.Patients were randomized to receive quetiapine 50 mg every 12 hrs or placebo. Quetiapine was increased every 24 hrs (50 to 100 to 150 to 200 mg every 12 hrs) if more than one dose of haloperidol was given in the previous 24 hrs. Study drug was continued until the intensive care unit team discontinued it because of delirium resolution, therapy > or = 10 days, or intensive care unit

2010 EvidenceUpdates

11. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. (PubMed)

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. To study rates of relapse in remitted patients with first episode psychosis who either continued or discontinued antipsychotic drugs after at least one year of maintenance treatment.12 month randomised, double blind, placebo controlled trial.Early psychosis outpatient clinics in Hong Kong.178 patients with first episode (...) psychosis who had received at least one year of antipsychotic drug treatment between September 2003 and July 2006 and had no positive symptoms of psychosis.Patients received either maintenance treatment with quetiapine (400 mg/day) or placebo and were followed up for the next 12 months or until a relapse occurred.Relapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content) according

Full Text available with Trip Pro

2010 BMJ

12. High- v low-dose quetiapine in schizophrenia: meta-analysis

High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis Painuly N CRD summary The review concluded that high-dose quetiapine was not superior to low doses in the acute treatment of schizophrenia, both in terms of efficacy and effectiveness. In light of the absence of an assessment of trial quality and the limited follow-up periods of the included trials, the author's (...) conclusion should be interpreted with a degree of caution. Authors' objectives To compare the effectiveness of high-dose and low-dose quetiapine in the acute treatment of schizophrenia. Searching PubMed, EMBASE, PsycINFO, AMED, CINHAL and Social SciSearch (SSCI) were searched to August 2007; search terms were reported. References lists of obtained articles were also searched. Study selection Double-blind, randomised controlled trials (RCTs) of the acute treatment of schizophrenia with fixed doses

Full Text available with Trip Pro

2010 DARE.

13. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Article Text Therapeutics Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

2010 Evidence-Based Mental Health

14. Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia (PubMed)

Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization.In a 6-week double-blind study, inpatients with a recent exacerbation of schizophrenia were randomly assigned to treatment with paliperidone extended-release, quetiapine, or placebo. A 2-week (...) monotherapy phase was followed by a 4-week additive-therapy phase. Target doses were at the upper end of recommended ranges: paliperidone extended-release, 9 or 12 mg/day, and quetiapine, 600 or 800 mg/day. The primary endpoint was the difference in mean total change score on the Positive and Negative Syndrome Scale (PANSS) between paliperidone extended-release and quetiapine at the 2-week monotherapy phase endpoint.Six-week completion rates were 77.5% (124/160) with paliperidone extended-release, 66.7

2009 EvidenceUpdates

15. Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults

Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation All Wales Medicines Strategy Group (AWMSG). Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1509. 2009 Authors' conclusions Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia

2009 Health Technology Assessment (HTA) Database.

16. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder (...) : results of a Markov model analysis Fajutrao L, Paulsson B, Liu S, Locklear J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of quetiapine added to lithium or valproate

2009 NHS Economic Evaluation Database.

17. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (PubMed)

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate Rapid-cycling bipolar disorder is often characterized by a lack of response to psychopharmacological treatment, and a standard therapy has not been developed yet. The aim of this study was to examine the long-term efficacy and safety of a monotherapy with quetiapine or sodium valproate (VPA) in patients with rapid-cycling bipolar disorder.This open-label, randomized, parallel group (...) monotherapy pilot study was conducted at 3 German centers. A sample of 38 remitted or partly remitted patients with bipolar disorder and rapid cycling (quetiapine n = 22; VPA n = 16) were treated with quetiapine or VPA (flexible dose design) for 12 months.Forty-one percent of the patients with quetiapine and 50% with VPA completed the trial. On the basis of ITT-LOCF, Life Chart Method data showed that patients being treated with quetiapine had significantly less moderate to severe depressive days than

2008 EvidenceUpdates

18. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study (PubMed)

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study Although many patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRIs for the treatment of OCD in severely (...) ill adult subjects.Forty patients (21 men, 19 women) with primary OCD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria participated in a 12-week, double-blind, placebo-controlled trial. They were randomly assigned to dosages of quetiapine titrated up to 400 mg/d (n = 20) or to placebo (n = 20) in addition to their SRI treatment. During the continuation phase (weeks 6-12), subjects received different dosages between 400 and 600 mg/d depending on clinical

2008 EvidenceUpdates

19. Quetiapine more effective than placebo for depression in bipolar I and II disorder

Quetiapine more effective than placebo for depression in bipolar I and II disorder Quetiapine more effective than placebo for depression in bipolar I and II disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine more effective than placebo for depression in bipolar I and II disorder Article Text Therapeutics Quetiapine more effective than placebo for depression in bipolar I and II disorder Statistics from Altmetric.com

2008 Evidence-Based Mental Health

20. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine

2008 Evidence-Based Mental Health